|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Diagnostic Test | |||||
| Other revenue | |||||
| Total revenue | |||||
| Cost of services | |||||
| Gross profit | |||||
| Research and development | |||||
| Selling and marketing | |||||
| General and administrative | |||||
| Impairment loss | |||||
| Other operating expenses, net | |||||
| Loss from operations | |||||
| Non-operating (expenses) income, net | |||||
| Change in fair market value of warrant and earn-out contingent liabilities | |||||
| Interest income (expense), net | |||||
| Change in fair value of financial liabilities | |||||
| Interest (expense) income, net | |||||
| Other (expense) income, net | |||||
| Total non-operating (expense) income, net | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| Net loss | |||||
| Other comprehensive income, net of tax | |||||
| Unrealized gain related to available for sale securities, net | |||||
| Comprehensive loss | |||||
| Basic weighted average shares outstanding of Class A common stock (in shares) | |||||
| Common Class A | |||||
| Total basic weighted average shares outstanding of Class A common stock (in shares) | |||||
| Diluted weighted average shares outstanding of Class A common stock (in shares) | |||||
| Common Class A | |||||
| Total diluted weighted average shares outstanding of Class A common stock (in shares) | |||||
| Basic net loss per share, Class A common stock (in dollars per share) | |||||
| Common Class A | |||||
| Total basic net loss per share, Class A common stock (in dollars per share) | |||||
| Diluted net loss per share, Class A common stock (in dollars per share) | |||||
| Common Class A | |||||
| Total diluted net loss per share, Class A common stock (in dollars per share) | |||||
Loading...